Blood Res.  2019 Mar;54(1):74-79. 10.5045/br.2019.54.1.74.

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag

• Yoon JK
• Jang HR
• Park JH
• Kim KH
• Roh EY
• Byun JM

• KMID: 2451059
• DOI: http://doi.org/10.5045/br.2019.54.1.74

Abstract

No abstract available.

MeSH Terms

Purpura, Thrombocytopenic, Idiopathic*
Thymoma*

Figure

• 

  Fig. 1 Chest computed tomography (A) at diagnosis, (B) after three cycles of CAP, and (C) six months after completion of chemotherapy.

• 

  Fig. 2 (A) Picture of bone marrow at diagnosis. The section shows normocellular marrow without malignant tumor cells (H&E stain, ×400). (B) Second bone marrow examination was performed before the third cycle of chemotherapy. The section (H&E stain, ×400) showed nearly normal distribution of nucleated cells without infiltrative tumor cells. (C) Final bone marrow examination was performed before administration of eltrombopag. The section (H&E stain, ×400) shows normocellular marrow with slightly increased megakaryocytes (right side).

• 

  Fig. 3 Treatment course and serial platelet counts.

Reference

1. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000; 96:3872–3879.

2. Rivoisy C, Besse B, Girard N, et al. Thymic epithelial tumor-associated cytopenia: a 10-year observational study in France. J Thorac Oncol. 2016; 11:391–399.

3. Qin J, Liu L. Thymoma with idiopathic thrombocytopenic purpura: report of a case. J Thorac Cardiovasc Surg. 2005; 129:453.

4. Onuki T, Kiyoki Y, Ueda S, Yamaoka M, Shimizu S, Inagaki M. Invasive thymoma with pure red cell aplasia and amegakaryocytic thrombocytopenia. Hematol Rep. 2016; 8:6680.

5. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004; 77:1183–1188.

6. Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol. 2011; 8:199–202.

7. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006; 135:405–407.

8. Maslovsky I, Gefel D, Uriev L, Ben Dor D, Lugassy G. Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura. Eur J Intern Med. 2005; 16:523–524.

9. Kobayashi H, Kitano K, Ishida F, et al. Aplastic anemia and idiopathic thrombocytopenic purpura with antibody to platelet glycoprotein IIb/IIIa following resection of malignant thymoma. Acta Haematol. 1993; 90:42–45.

10. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357:2237–2247.

11. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377:393–402.